Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.1K
Cancer Survival Analysis01:21

Cancer Survival Analysis

863
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
863
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

475
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
475
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

701
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
701
Factors Affecting Illness01:18

Factors Affecting Illness

5.4K
When a person's physical, emotional, intellectual, social development or spiritual functioning is compromised, this deviation from a healthy normal state is called illness. Illness creates stress that in turn harms individuals. Irritation, anger, denial, hopelessness, and fear are behavioral and emotional changes an individual experiences in the phases of illness. A variety of factors influence a person's health and well-being.
For instance, risk factors are connected to illness,...
5.4K
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

8.3K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review.

Blood research·2026
Same author

Perceptions and Use of Complementary and Alternative Medicine among Patients with Cancer and Their Family Members (KCSG PC21-19).

Cancer research and treatment·2026
Same author

Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling-guided therapy in advanced cancers.

International journal of clinical oncology·2026
Same author

Paired ctDNA analysis reveals diverse resistance mechanisms to mobocertinib in EGFR exon 20 insertion NSCLC.

Frontiers in oncology·2026
Same author

Allogeneic stem cell transplantation for myelofibrosis in the modern era: Single-center outcomes with DIPSS risk stratification.

Blood research·2026
Same author

Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Annals of hematology·2026

Related Experiment Video

Updated: May 3, 2026

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

9.1K

Prognostic factor analysis in core-binding factor-positive acute myeloid leukemia.

Hyun Ae Jung1, Chi Hoon Maeng, Silvia Park

  • 1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea. jh21.jang@samsung.com, chulwon1.jung@samsung.com.

Anticancer Research
|February 11, 2014
PubMed
Summary

Core binding factor-acute myeloid leukemia (AML) with t(8;21) or inv(16) has variable outcomes. Deletion of the Y chromosome may indicate a favorable prognosis in these AML patients.

Keywords:
Core-binding factor-positive AMLprognostic factor

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.3K

Related Experiment Videos

Last Updated: May 3, 2026

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

9.1K
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

13.9K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.3K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Acute myeloid leukemia (AML) with specific chromosomal translocations, t(8;21) or inv(16), generally indicates a favorable prognosis.
  • However, the prognostic outlook for these AML subtypes is not uniform and can be influenced by additional genetic alterations.

Purpose of the Study:

  • To investigate the impact of cytogenetic variables and additional molecular aberrations on treatment outcomes in patients with t(8;21) or inv(16) AML.
  • To identify prognostic factors that contribute to the heterogeneity of outcomes in core binding factor-positive AML.

Main Methods:

  • A retrospective analysis was conducted on 67 patients diagnosed with t(8;21) or inv(16) AML between January 2000 and December 2010.
  • Collected data included cytogenetic variables and treatment outcomes.

Main Results:

  • Of the 67 patients, 51 had t(8;21) AML and 16 had inv(16) AML.
  • Factors associated with poor overall survival included thrombocytopenia and a high percentage of blasts in peripheral blood and bone marrow.
  • Additional chromosomal abnormalities were observed in 49% of t(8;21) patients and 37.5% of inv(16) patients, with deletion of the Y or X chromosome being the most common.

Conclusions:

  • Deletion of the Y chromosome may serve as a favorable prognostic indicator in patients with core binding factor-positive AML.
  • Further research is warranted to elucidate the role of specific chromosomal abnormalities in refining AML prognostication.